Opus Genetics Inc. has released its financial results for the second quarter ended June 30, 2025. The company reported a total license and collaboration revenue of $2.9 million, showing a significant increase compared to $1.1 million in the same period of 2024. This revenue growth was primarily driven by the company's collaboration with Viatris, Inc., mainly from the reimbursement of R&D services. General and administrative expenses for the quarter rose to $5.8 million from $3.4 million in the same quarter of the previous year. The increase in expenses was largely attributed to higher costs related to legal and patent-related activities, payroll, and business development efforts. Stock-based compensation accounted for $0.6 million of the G&A expenses in 2025, a slight increase from $0.5 million in 2024. Opus Genetics' cash and cash equivalents stood at $32.4 million as of June 30, 2025. The company anticipates that its existing cash reserves will support operations into the second half of 2026, based on its current operating plans. Significant developments in the company's operations include positive 12-month Phase 1/2 clinical data in adult cohorts and early pediatric clinical data for OPGx-LCA5, which support the potential for meaningful vision restoration. The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5. Additionally, Opus Genetics reported positive topline results from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75%. The company is also on track to initiate a Phase 1/2 trial for OPGx-BEST1 in the second half of 2025 and has secured non-dilutive funding from patient advocacy groups to advance multiple early-stage gene therapy programs.